ID
45157
Beschrijving
Principal Investigator: Alan Shuldiner, MD, University of Maryland Baltimore, Baltimore, MD, USA MeSH: Pharmacogenomics,Clopidogrel,Platelets https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000391 CHD is the leading cause of death in the United States. One of the most common ways to prevent CHD is to take an anti-platelet agent, which lessens platelet aggregation. Two of the most common anti-platelet agents are aspirin and clopidogrel. However, up to 25% to 30% of people do not respond to these medications. Evidence indicates that treatment response may be related to genetics. The purpose of this study is to determine specific gene variants that predict response to aspirin and clopidogrel therapy. This study is part of a larger group of studies called the Pharmacogenomics Research Network (PGRN). Participants are from the Old Order Amish of Lancaster, Pennsylvania. They are well suited for genetic studies because they are a homogenous, closed, founder population. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before and after clopidogrel alone, and then again after taking clopidogrel plus aspirin. Using the gene variation profiles across the genome, researchers analyzed which variants correspond to treatment response.
Link
Trefwoorden
Versies (2)
- 02-09-22 02-09-22 - Niko Möller-Grell
- 12-10-22 12-10-22 - Adrian Schulz
Houder van rechten
Alan Shuldiner, MD, University of Maryland Baltimore, Baltimore, MD, USA
Geüploaded op
12 oktober 2022
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000391 Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study
Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID and sample ID of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID, age, sex, body mass index, systolic and diastolic blood pressure, waist circumference, fasting triglycerides, total cholesterol, LHD, HDL, baseline whole blood max aggregation of ADP, of arachidonic acid, and collagen 1, post plavix/pre aspirin whole blood max aggregation of ADP, of arachadonic acid, and collagen 1, baseline platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, and arachadonic acid, post plavix/pre aspirin platelet rich plasma max aggregation of ADP, of Epi, and arachadonic acid, post plavix/post aspirin platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, of arachadonic acid obtained from participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
Similar models
Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID and sample ID of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID, age, sex, body mass index, systolic and diastolic blood pressure, waist circumference, fasting triglycerides, total cholesterol, LHD, HDL, baseline whole blood max aggregation of ADP, of arachidonic acid, and collagen 1, post plavix/pre aspirin whole blood max aggregation of ADP, of arachadonic acid, and collagen 1, baseline platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, and arachadonic acid, post plavix/pre aspirin platelet rich plasma max aggregation of ADP, of Epi, and arachadonic acid, post plavix/post aspirin platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, of arachadonic acid obtained from participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.